VIENTIANE, LAOS, SEPTEMBER 24, 2024 — Recently, Big Bear Pharma Laos announced that it has obtained official approval from the Lao Ministry of Health for the first export of its anticancer drug Mitotane (trade name: MITODX) to Malaysia, achieving a historic dual “zero” breakthrough for Laos’ pharmaceutical industry!
First approved for marketing in 1960, Mitotane is long past its patent expiration. Owing to its orphan drug status, few pharmaceutical manufacturers are willing to produce this product. With the support of RxLibra, its international marketing and promotion service provider, Big Bear Pharma Laos has now accomplished two groundbreaking “firsts” for Laos’ pharmaceutical sector:
It marks the first time a Lao pharmaceutical enterprise has exported an anticancer drug!
It marks the first time a Lao pharmaceutical enterprise has exported an orphan drug!
The successful entry of MITODX into the international market not only attests to Big Bear Pharma Laos’ recognition by global customers, but also signifies that Laos’ pharmaceutical industry has achieved quality improvement and efficiency enhancement, elevating itself to a new level. The company’s acquisition of export approval and successful completion of this trade also means that the drug has brought new treatment options to patients across the ASEAN region.
